Shenzhen - Delayed Quote CNY

Tellgen Corporation (300642.SZ)

13.94
+0.10
+(0.72%)
At close: May 16 at 3:04:43 PM GMT+8
Loading Chart for 300642.SZ
  • Previous Close 13.84
  • Open 14.04
  • Bid 13.93 x --
  • Ask 13.94 x --
  • Day's Range 13.77 - 13.99
  • 52 Week Range 10.65 - 19.20
  • Volume 1,454,300
  • Avg. Volume 3,619,479
  • Market Cap (intraday) 2.273B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 58.08
  • EPS (TTM) 0.24
  • Earnings Date --
  • Forward Dividend & Yield 0.15 (1.08%)
  • Ex-Dividend Date May 20, 2025
  • 1y Target Est --

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; cardiovascular and inflammation; biochemistry kits; DNA methylation testing kits; and molecular detection of COVID-19 and others. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.

www.tellgen.com

522

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300642.SZ

View More

Performance Overview: 300642.SZ

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300642.SZ
1.27%
SSE Composite Index (000001.SS)
0.47%

1-Year Return

300642.SZ
0.75%
SSE Composite Index (000001.SS)
7.85%

3-Year Return

300642.SZ
34.52%
SSE Composite Index (000001.SS)
9.56%

5-Year Return

300642.SZ
43.27%
SSE Composite Index (000001.SS)
17.40%

Compare To: 300642.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300642.SZ

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    2.27B

  • Enterprise Value

    1.90B

  • Trailing P/E

    57.22

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.40

  • Price/Book (mrq)

    1.51

  • Enterprise Value/Revenue

    4.53

  • Enterprise Value/EBITDA

    45.23

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.44%

  • Return on Assets (ttm)

    2.56%

  • Return on Equity (ttm)

    2.20%

  • Revenue (ttm)

    418.6M

  • Net Income Avi to Common (ttm)

    39.49M

  • Diluted EPS (ttm)

    0.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    484.82M

  • Total Debt/Equity (mrq)

    6.91%

  • Levered Free Cash Flow (ttm)

    -15.92M

Research Analysis: 300642.SZ

View More

Company Insights: 300642.SZ

Research Reports: 300642.SZ

View More

People Also Watch